Clopidogrel use and clinical events after drug-eluting stent implantation: Findings from the HealthCore Integrated Research Database

American Heart Journal

Volumn 159, Issue 3, 2010, Pages

  Petersen, John L ^a,b   Barron, John J ^c   Hammill, Bradley G ^a   Cziraky, Mark J ^c   Anstrom, Kevin J ^a,b   Wahl, Peter M ^c   Eisenstein, Eric L ^a,b   Krucoff, Mitchell W ^a,b   Califf, Robert M ^a,b   Schulman, Kevin A ^a,b   Curtis, Lesley H ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HEALTHCORE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG SAFETY; DRUG USE; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77649101426     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.11.031     Document Type: Article

References (40)

1. Bavry A.A., Kumbhani D.J., Helton T.J., et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
2. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 48 (2006) 2584-2591
3. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long term-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
4. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
5. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
6. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal in Sweden. N Engl J Med 356 (2007) 1009-1019
7. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug eluting stents. N Engl J Med 356 (2007) 1020-1029
8. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
9. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
10. Marzocchi A., Saia F., Piovaccari G., et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115 (2007) 3181-3188
11. Daemen J., Tanimoto S., Garcia-Garcia H.M., et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries). Am J Cardiol 99 (2007) 1027-1032
12. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
13. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
14. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
15. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) event with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
16. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
17. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and non-diabetic patients. J Am Coll Cardiol 50 (2007) 501-508
18. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
19. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
20. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
21. James S.K., Stenestrand U., Lindbäck J., et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 360 (2009) 1933-1945
22. Yusuf S., Zhao F., Mehta S.R., et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
23. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288 (2002) 2411-2420
24. Bhatt D.L., Flather M.D., Hacke W., et al. Patients with prior myocardial infarction, stroke or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
25. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
26. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Intervention, American College of Surgeons, and American Dental Association, with representation from American College of Physicians. Circulation 115 (2007) 813-818
27. Becker R.C., Meade T.W., Berger P.B., et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008) 776S-814S
28. Bavery A.A., and Bhatt D.L. Drug-eluting stents: dual antiplatelet therapy for every survivor?. Circulation 116 (2007) 696-699
29. Mosca L., Merz N.B., Blumenthal R.S., et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
30. Instructions for use: CYPHER™ sirolimus eluting coronary stent on RAPTOR™ over-the-wire delivery system. http://www.fda.gov/cdrh/PDF2/p020026c.pdf Last accessed May 22, 2008
31. Sarawate C.A., Brewer K.K., Yang W., et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81 (2006) 925-934
32. Arnason T., Wells P.S., van Walraven C., et al. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 118 (2006) 253-262
33. Social Security death index. http://www.ntis.gov/products/pages/ssa-death-master.asp Last accessed February 22, 2008
34. Cole S.R., and Hernán M.A. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75 (2004) 45-49
35. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
36. Nikolsky E., Mehran R., Dangas G., et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 28 (2007) 1936-1945
37. Rao S.V., Jollis J., Harrington R.A., et al. Relationship between blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
38. Stone G.W., Ellis S.G., Colombo A., et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115 (2007) 2842-2847
39. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
40. Ho P.M., Peterson E.D., Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539